Dossier
high-risk groups
Coverage of high-risk groups in the Nexus archive.
- Lenacapavir will slow HIV infections if there's enough of it and it reaches at-risk groups
Lenacapavir is an HIV prevention injection administered twice a year, offering an improvement over daily pills for high-risk groups. Its long-term effectiveness depends on sufficient supply and distribution to those at risk.